Docality.com Logo
 
Dr. John  Zimmermann  Md image

Dr. John Zimmermann Md

2490 S Woodworth Loop #499
Palmer AK 99645
907 467-7771
Medical School: Other - 2000
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #:
NPI: 1740221225
Taxonomy Codes:
207RX0202X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. John Zimmermann is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:J9045 Description:Carboplatin injection Average Price:$2,400.00 Average Price Allowed
By Medicare:
$3.48
HCPCS Code:96413 Description:Chemo iv infusion 1 hr Average Price:$605.00 Average Price Allowed
By Medicare:
$151.25
HCPCS Code:J2469 Description:Palonosetron hcl Average Price:$449.99 Average Price Allowed
By Medicare:
$18.79
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$600.00 Average Price Allowed
By Medicare:
$255.81
HCPCS Code:96365 Description:Ther/proph/diag iv inf init Average Price:$420.00 Average Price Allowed
By Medicare:
$80.04
HCPCS Code:96375 Description:Tx/pro/dx inj new drug addon Average Price:$273.00 Average Price Allowed
By Medicare:
$25.31
HCPCS Code:J1200 Description:Diphenhydramine hcl injectio Average Price:$243.00 Average Price Allowed
By Medicare:
$0.76
HCPCS Code:96417 Description:Chemo iv infus each addl seq Average Price:$303.00 Average Price Allowed
By Medicare:
$78.59
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$400.00 Average Price Allowed
By Medicare:
$204.06
HCPCS Code:96367 Description:Tx/proph/dg addl seq iv inf Average Price:$210.00 Average Price Allowed
By Medicare:
$37.16
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$247.50 Average Price Allowed
By Medicare:
$88.51
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$275.00 Average Price Allowed
By Medicare:
$131.86
HCPCS Code:80053 Description:Comprehen metabolic panel Average Price:$126.50 Average Price Allowed
By Medicare:
$14.97
HCPCS Code:J1453 Description:Fosaprepitant injection Average Price:$100.00 Average Price Allowed
By Medicare:
$1.72
HCPCS Code:85025 Description:Complete cbc w/auto diff wbc Average Price:$83.00 Average Price Allowed
By Medicare:
$11.02
HCPCS Code:96372 Description:Ther/proph/diag inj sc/im Average Price:$90.00 Average Price Allowed
By Medicare:
$28.15
HCPCS Code:36415 Description:Routine venipuncture Average Price:$47.00 Average Price Allowed
By Medicare:
$3.00
HCPCS Code:J2780 Description:Ranitidine hydrochloride inj Average Price:$36.00 Average Price Allowed
By Medicare:
$1.05
HCPCS Code:J1100 Description:Dexamethasone sodium phos Average Price:$20.00 Average Price Allowed
By Medicare:
$0.12

HCPCS Code Definitions

96367
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)
96365
Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
J1453
Injection, fosaprepitant, 1 mg
J1200
Injection, diphenhydramine hcl, up to 50 mg
96372
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96413
Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96375
Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)
J1100
Injection, dexamethasone sodium phosphate, 1mg
96417
Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
J2469
Injection, palonosetron hcl, 25 mcg
J9045
Injection, carboplatin, 50 mg
J2780
Injection, ranitidine hydrochloride, 25 mg

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1346238474
Hematology/Oncology
9,350
1740243914
Hematology/Oncology
5,583
1578522694
Internal Medicine
1,083
1770664898
Cardiovascular Disease (Cardiology)
998
1619077476
Diagnostic Radiology
973
1285727883
Radiation Oncology
697
1770681298
Radiation Oncology
544
1841209368
Cardiovascular Disease (Cardiology)
522
1932157245
General Surgery
445
1366443871
General Surgery
401
*These referrals represent the top 10 that Dr. Zimmermann has made to other doctors

Publications

Qualification of cardiac troponin I concentration in mouse serum using isoproterenol and implementation in pharmacology studies to accelerate drug development. - Toxicologic pathology
Cardiac troponin I is a useful biomarker of myocardial injury, but its use in mice and application to early drug discovery are not well described. The authors investigated the relationship between cTnI concentration in serum and histologic lesions in heart tissue from mice treated with isoproterenol (ISO). Cardiac TnI concentrations in serum increased in a dose-dependant manner and remained increased twenty-four to forty-eight hours after a single administration of isoproterenol. Increased cTnI concentration was of greater magnitude and longer duration than increased fatty acid binding protein 3 concentration, aspartate aminotransferase activity, and creatine kinase activity in serum. Isoproterenol-induced increases in cTnI concentrations were both greater and more sustained in BALB/c than in CD1 mice and correlated with incidence and severity of lesions observed in heart sections from both strains. In drug development studies in BALB/c mice with novel kinase inhibitors, cTnI concentration was a reliable stand-alone biomarker of cardiac injury and was used in combination with measurements of in vivo target inhibition to demonstrate an off-target contribution to cardiotoxicity. Additional attributes, including low cost and rapid turnaround time, made cTnI concentration in serum invaluable for detecting cardiotoxicity, exploring structure-activity relationships, and prioritizing development of compounds with improved safety profiles early in drug discovery.
Age-related changes in adenosine metabolic enzymes in sleep/wake regulatory areas of the brain. - Neurobiology of aging
The impact of age on the enzymatic activities of adenosine metabolic enzymes, i.e., adenosine deaminase, adenosine kinase, cytosolic- and ecto-5'-nucleotidase have been assessed in the brain sleep/wake regulatory areas of young, intermediate and old rats (2, 12 and 24 months, respectively). There were significant spatial differences in the distribution of enzymes of adenosine metabolism in the brain. Age did not impact on the enzymatic activity of adenosine deaminase. Adenosine kinase activity increased significantly in the cerebral cortex of old animals. However, there were no differences in the activity of adenosine kinase between young and intermediate aged rats. The largest age-related changes were in the activity of cytosolic- and ecto-5'-nucleotidase and there was a significant age-related increase in the activity of these enzymes in the sleep/wake regulatory areas. In addition, the activity of cytosolic- and ecto-5'-nucleotidase increased in the cerebral cortex of old and intermediate age rats when compared to young animals. An increase in the enzymatic activities in the cerebral cortex of adenosine kinase and 5'-nucleotideases was accompanied by an increase in the level of their mRNA. An increase in the activity of 5'-nucleotideases with age likely leads to an increase in adenosine levels in the brain.
Evaluation of the erythroid regenerative response in two different models of experimentally induced iron deficiency anemia. - Veterinary clinical pathology / American Society for Veterinary Clinical Pathology
Anemia was induced in weanling Sprague Dawley rats either by feeding an iron-deficient diet or by chronic phlebotomy. The erythroid regenerative response was then evaluated before and after a hemolytic event, and results were compared with those of a third group of control nonphlebotomized rats fed an iron-replete diet. Diet and phlebotomy groups developed a similar degree of anemia (mean hemoglobin concentration 7.9 g/dL and 7.8 g/dL, respectively; controls, 13.9 g/dL) and hypoferremia (mean serum iron concentration 25.4 microgram/dL and 34.9 microgram/dL, respectively; controls, 222.0 microgram/dL). However, the anemia in diet rats was nonregenerative (reticulocyte count, 83.1 X 10(3) cells/microliter) and associated with bone marrow erythroid hypoplasia; whereas the anemia in phlebotomy rats was regenerative (reticulocyte count, 169.6 X 10(3) cells/microliter) and associated with bone marrow erythroid hyperplasia. Thrombocytosis was seen in diet rats (1,580 X 10(3) cells/microliter) but not phlebotomy rats (901 X 10(3) cells/microliter) when compared with controls (809 X 10(3) cells/microliter). To further evaluate the regenerative capability, phenylhydrazine (PHZ) was administered to induce hemolysis. Erythrocyte mass declined approximately 25% in all groups, including controls. The reticulocytosis (265.3 X 10(3) cells/microliter) seen in phlebotomy rats was earlier and significantly greater than that seen in either diet or control rats. Hemoglobin concentration returned to pre-PHZ concentrations (7.9 g/dL) in phlebotomy rats within 4 days posthemolysis. In diet rats, the maximal regenerative response (176.3 X 10(3) cells/microliter) was not seen until 8 days posthemolysis, and hemoglobin (7.5 g/dL) did not return to pre-PHZ concentrations during the 8-day study. In many aspects, the anemia seen following diet- or phlebotomy-induced iron deficiency was similar. However, the erythroid regenerative capability varied depending on the mechanism by which anemia was induced and furthermore altered the efficiency of hemoglobin production following a hemolytic event. These results suggest that the availability of iron in the diet may modulate the pathogenesis of iron deficiency anemia.
Increasing throughput in lead optimization in vivo toxicity screens. - Current opinion in drug discovery & development
Lead optimization requires toxicity screening strategies to select a compound with a high likelihood of successful development. As numerous compounds need to be screened and resources to direct toward any single compound are limited, short turnaround times to generate and interpret data are needed. Utilization of in vivo toxicity screens is necessary for an effective screening strategy, however, if not appropriately implemented, they may consume excessive resources and prolong selection of a developable compound. Optimization of in vivo studies requires identifying effective placement into the screening strategy, selecting the appropriate study designs, implementing processes that allow rapid data generation and interpretation, and understanding the utilities of in vivo data. When implemented, an effective, high-throughput screening strategy will utilize adequate but minimal amounts of resources, and will prioritize processing near technical time limits. These require generating only the data from which decisions will be made and can be best achieved using as few animals as possible per study.

Map & Directions

2490 S Woodworth Loop #499 Palmer, AK 99645
View Directions In Google Maps

Nearby Doctors

2490 S. Woodworth Loop Suite 350
Palmer, AK 99645
907 452-2663
2490 S Woodworth Loop Suite 310
Palmer, AK 99645
907 457-7575
2500 S Woodworth Loop
Palmer, AK 99645
907 616-6000
2500 S Woodworth Loop
Palmer, AK 99645
907 829-9884
2490 S Woodworth Loop Suite 201
Palmer, AK 99645
907 459-9200
6921 E. Garth Circle
Palmer, AK 99645
907 761-1633
2500 S Woodworth Loop
Palmer, AK 99645
907 450-0374
2250 S Woodworth Loop Suite 101
Palmer, AK 99645
907 615-5900
2490 S Woodworth Loop Suite 400
Palmer, AK 99645
907 459-9401
634 S Bailey St Ste 104
Palmer, AK 99645
907 462-2345